Drug Trial Radar · NCT06100887
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
43
Actual
Start
Mar 22, 2024
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.
Conditions
- Duchenne Muscular Dystrophy
Interventions
Sevasemten Dose 1Drug
Sevasemten is administered orally once per day
Sevasemten Dose 2Drug
Sevasemten is administered orally once per day
Sevasemten Dose 3Drug
Sevasemten is administered orally once per day
PlaceboDrug
Placebo is administered orally once per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse events during treatment with sevasemten or placeboTime frame: 36 months
- Severity of adverse events during treatment with sevasemten or placeboTime frame: 36 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California
UC Davis Medical Center
Sacramento, California
University of Florida
Gainesville, Florida
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Rare Disease Research
Hillsborough, North Carolina
Nationwide Children's Hospital
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.